Vanguard Global Advisers
APGE icon

Vanguard Global Advisers’s Apogee Therapeutics APGE Stock Holding History

Vanguard Global Advisers’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.88M Sell
21,677
-2,719
-11% -$245K ﹤0.01% 1033
2026
Q1 		$2.05M Buy
+24,396
New +$1.77M ﹤0.01% 1176

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Vanguard Global Advisers's APGE Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Apogee Therapeutics (APGE) stake by 11% in Q2 2026, selling an estimated $245K and leaving 21,677 shares worth $2.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1033.

Vanguard Global Advisers first reported a position in APGE in Q1 2026 and has held it in 2 quarters since. 283 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Vanguard Global Advisers held 21,677 shares of Apogee Therapeutics worth $2.88M as of Q2 2026.
  • Vanguard Global Advisers sold 2,719 Apogee Therapeutics shares in Q2 2026, an estimated $245K.
  • Apogee Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1033 holding.
  • Vanguard Global Advisers first reported a position in Apogee Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 283 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.